| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRRE.2013.04.002 |
| P698 | PubMed publication ID | 23747093 |
| P50 | author | Julien Zuber | Q42859640 |
| P2093 | author name string | Christophe Legendre | |
| Alexandre Loupy | |||
| Dany Anglicheau | |||
| Marion Rabant | |||
| Marc-Olivier Timsit | |||
| Rébecca Sberro-Soussan | |||
| P2860 | cites work | Atypical hemolytic-uremic syndrome | Q33386736 |
| New insights into postrenal transplant hemolytic uremic syndrome. | Q33392948 | ||
| Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. | Q33403196 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Diagnosis and prevention of chronic kidney allograft loss | Q34224452 | ||
| Strategies to improve long-term outcomes after renal transplantation | Q34539775 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Challenges and considerations in diagnosing the kidney disease in deteriorating graft function | Q36365811 | ||
| Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria | Q37956407 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 | ||
| The role of complement in the early immune response to transplantation. | Q38013049 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. | Q38049098 | ||
| Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study | Q39883589 | ||
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts | Q45287212 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 90-92 | |
| P577 | publication date | 2013-06-07 | |
| P1433 | published in | Transplantation Reviews | Q15749559 |
| P1476 | title | Eculizumab in renal transplantation | |
| P478 | volume | 27 |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q26796453 | Advances and challenges in the management of complement-mediated thrombotic microangiopathies |
| Q38718092 | Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals. |
| Q33419812 | Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q90871287 | Endothelium structure and function in kidney health and disease |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
| Q37243068 | Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q42364725 | Stratification of responders towards eculizumab using a structural epitope mapping strategy |
| Q37200645 | Successful Salvage Treatment of Resistant Acute Antibody-Mediated Kidney Transplant Rejection with Eculizumab |
| Q43421536 | Understanding Trends in Kidney Function 1 Year after Kidney Transplant in the United States |
| Q56896789 | Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplant |
Search more.